wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26748614-424DF69E-61EC-4A83-BB38-EFD209732F8C
Q26748614-424DF69E-61EC-4A83-BB38-EFD209732F8C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26748614-424DF69E-61EC-4A83-BB38-EFD209732F8C
Posttranslational Modifications and the Immunogenicity of Biotherapeutics
P2860
Q26748614-424DF69E-61EC-4A83-BB38-EFD209732F8C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26748614-424DF69E-61EC-4A83-BB38-EFD209732F8C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b5f4a183a121c598e868d7485e5806fcb46ced36
P2860
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.